ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap
To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meetin...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-11-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024916300481 |
| id |
doaj-31c0023f19ae480299b2c0347a697892 |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Hans-Joachim Anders Brad Rovin David Jayne Paul Brunetta Rosanna Coppo Anne Davidson Satish Kumar Devarapu Dick de Zeeuw Jeremy Duffield Dirk Eulberg Alberto Fierro Jürgen Floege Steffen Frese Loïc Guillevin Stephen Holdsworth Jeremy Hughes Ralph Kettritz Malte Kluger Christian Krebs Larissa Lapteva Adeera Levin Jinhua Li Liz Lightstone Matthias Mack Ladan Mansouri Stephen McAdoo Eoin McKinney Ulf Panzer Samir Parikh Charles Pusey Chaim Putterman Ton Rabelink Andreas Radbruch Andrew Rees Mary Reilly Marlies Reinders Giuseppe Remuzzi Piero Ruggenenti Steven Sacks Thomas J Schall Catherine Meyer-Schwesinger Kumar Sharma Yusuke Suzuki Nicola M. Tomas Ming-Hui Zhao |
| spellingShingle |
Hans-Joachim Anders Brad Rovin David Jayne Paul Brunetta Rosanna Coppo Anne Davidson Satish Kumar Devarapu Dick de Zeeuw Jeremy Duffield Dirk Eulberg Alberto Fierro Jürgen Floege Steffen Frese Loïc Guillevin Stephen Holdsworth Jeremy Hughes Ralph Kettritz Malte Kluger Christian Krebs Larissa Lapteva Adeera Levin Jinhua Li Liz Lightstone Matthias Mack Ladan Mansouri Stephen McAdoo Eoin McKinney Ulf Panzer Samir Parikh Charles Pusey Chaim Putterman Ton Rabelink Andreas Radbruch Andrew Rees Mary Reilly Marlies Reinders Giuseppe Remuzzi Piero Ruggenenti Steven Sacks Thomas J Schall Catherine Meyer-Schwesinger Kumar Sharma Yusuke Suzuki Nicola M. Tomas Ming-Hui Zhao ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap Kidney International Reports autoimmunity inflammation lupus rejection stem cells vasculitis |
| author_facet |
Hans-Joachim Anders Brad Rovin David Jayne Paul Brunetta Rosanna Coppo Anne Davidson Satish Kumar Devarapu Dick de Zeeuw Jeremy Duffield Dirk Eulberg Alberto Fierro Jürgen Floege Steffen Frese Loïc Guillevin Stephen Holdsworth Jeremy Hughes Ralph Kettritz Malte Kluger Christian Krebs Larissa Lapteva Adeera Levin Jinhua Li Liz Lightstone Matthias Mack Ladan Mansouri Stephen McAdoo Eoin McKinney Ulf Panzer Samir Parikh Charles Pusey Chaim Putterman Ton Rabelink Andreas Radbruch Andrew Rees Mary Reilly Marlies Reinders Giuseppe Remuzzi Piero Ruggenenti Steven Sacks Thomas J Schall Catherine Meyer-Schwesinger Kumar Sharma Yusuke Suzuki Nicola M. Tomas Ming-Hui Zhao |
| author_sort |
Hans-Joachim Anders |
| title |
ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap |
| title_short |
ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap |
| title_full |
ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap |
| title_fullStr |
ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap |
| title_full_unstemmed |
ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap |
| title_sort |
isn nexus 2016 symposia: translational immunology in kidney disease—the berlin roadmap |
| publisher |
Elsevier |
| series |
Kidney International Reports |
| issn |
2468-0249 |
| publishDate |
2016-11-01 |
| description |
To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases. |
| topic |
autoimmunity inflammation lupus rejection stem cells vasculitis |
| url |
http://www.sciencedirect.com/science/article/pii/S2468024916300481 |
| work_keys_str_mv |
AT hansjoachimanders isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT bradrovin isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT davidjayne isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT paulbrunetta isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT rosannacoppo isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT annedavidson isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT satishkumardevarapu isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT dickdezeeuw isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT jeremyduffield isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT dirkeulberg isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT albertofierro isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT jurgenfloege isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT steffenfrese isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT loicguillevin isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT stephenholdsworth isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT jeremyhughes isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT ralphkettritz isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT maltekluger isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT christiankrebs isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT larissalapteva isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT adeeralevin isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT jinhuali isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT lizlightstone isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT matthiasmack isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT ladanmansouri isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT stephenmcadoo isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT eoinmckinney isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT ulfpanzer isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT samirparikh isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT charlespusey isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT chaimputterman isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT tonrabelink isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT andreasradbruch isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT andrewrees isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT maryreilly isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT marliesreinders isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT giusepperemuzzi isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT pieroruggenenti isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT stevensacks isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT thomasjschall isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT catherinemeyerschwesinger isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT kumarsharma isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT yusukesuzuki isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT nicolamtomas isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap AT minghuizhao isnnexus2016symposiatranslationalimmunologyinkidneydiseasetheberlinroadmap |
| _version_ |
1725482418386763776 |
| spelling |
doaj-31c0023f19ae480299b2c0347a6978922020-11-24T23:49:24ZengElsevierKidney International Reports2468-02492016-11-011432733910.1016/j.ekir.2016.06.009ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin RoadmapHans-Joachim Anders0Brad Rovin1David Jayne2Paul Brunetta3Rosanna Coppo4Anne Davidson5Satish Kumar Devarapu6Dick de Zeeuw7Jeremy Duffield8Dirk Eulberg9Alberto Fierro10Jürgen Floege11Steffen Frese12Loïc Guillevin13Stephen Holdsworth14Jeremy Hughes15Ralph Kettritz16Malte Kluger17Christian Krebs18Larissa Lapteva19Adeera Levin20Jinhua Li21Liz Lightstone22Matthias Mack23Ladan Mansouri24Stephen McAdoo25Eoin McKinney26Ulf Panzer27Samir Parikh28Charles Pusey29Chaim Putterman30Ton Rabelink31Andreas Radbruch32Andrew Rees33Mary Reilly34Marlies Reinders35Giuseppe Remuzzi36Piero Ruggenenti37Steven Sacks38Thomas J Schall39Catherine Meyer-Schwesinger40Kumar Sharma41Yusuke Suzuki42Nicola M. Tomas43Ming-Hui Zhao44Medizinische Klinik and Poliklinik IV, Klinikum der Ludwig Maximilians Universität München, Munich, GermanyOhio State University Wexner Medical Center, Columbus, Ohio, USAVasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UKDevelopment Team for Rituximab and Obinutuzumab Immunology, Genentech, South San Francisco, California, USAAOU Città della Salute e della Scienza di Torino, Turin and Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, ItalyCenter for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, New York, USAMedizinische Klinik and Poliklinik IV, Klinikum der Ludwig Maximilians Universität München, Munich, GermanyDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the NetherlandsResearch & Development, Biogen, Cambridge, Massachusetts, USANOXXON Pharma AG, Berlin, GermanyClinica las Condes, Transplantation Unit, Santiago, ChileDepartment of Nephrology and Clinical Immunology, University Hospital, Rheinisch Westfälische Technische Hochschule Aachen, Aachen, GermanyEvangelische Lungenklinik Berlin, Klinik für Thoraxchirurgie, Berlin, GermanyUniversité Paris Descartes and Hôpital Cochin, Paris, FranceCentre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, Victoria, AustraliaMedical Research Council Centre for Inflammation Research, University of Edinburgh, Edinburgh, UKDepartment of Nephrology and Critical-Care Medicine, Campus Virchow Klinikum and Experimental and Clinical Research Center, Charité Medical Faculty, Berlin, GermanyZentrum für Innere Medizin, III. Medizinische Klinik und Poliklinik, University Medical Center, Hamburg, GermanyZentrum für Innere Medizin, III. Medizinische Klinik und Poliklinik, University Medical Center, Hamburg, GermanyDivision of Therapeutic Performance, Food and Drug Administration, Silver Spring, Maryland, USADivision of Nephrology, University of British Columbia, Vancouver, CanadaDepartment of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, AustraliaImperial AHSC Lupus Centre, Department of Medicine, Imperial College London, London, UKUniversität Regensburg, Klinik und Poliklinik für Innere Medizin II, Regensburg, GermanyUnit of Immunology and Allergy, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Solna, Stockholm, SwedenRenal and Vascular Inflammation Section, Department of Medicine, Imperial College London, UKDepartment of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, UKZentrum für Innere Medizin, III. Medizinische Klinik und Poliklinik, University Medical Center, Hamburg, GermanyOhio State University Wexner Medical Center, Columbus, Ohio, USARenal and Vascular Inflammation Section, Department of Medicine, Imperial College London, UKDivision of Rheumatology, Albert Einstein College of Medicine, Bronx, New York, USADepartment of Nephrology, Leiden University Medical Center, Leiden, the NetherlandsDeutsches Rheuma-Forschungszentrum Berlin, Berlin, GemanyClinical Institute of Pathology, Medical University of Vienna, Vienna, AustriaPharmaceutical Development, Opsona Therapeutics Ltd., Dublin 2, IrelandDepartment of Nephrology, Leiden University Medical Center, Leiden, the NetherlandsIRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Bergamo, ItalyIRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Bergamo, ItalyMRC Centre for Transplantation Immunology and Mucosal Biology, King’s College London, UKChemoCentryx, Mountain View, California, USAZentrum für Innere Medizin, III. Medizinische Klinik und Poliklinik, University Medical Center, Hamburg, GermanyCenter for Renal Translational Medicine, Institute of Metabolomic Medicine, University of California, San Diego, San Diego VA Healthcare System, La Jolla, California, USADivision of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, JapanZentrum für Innere Medizin, III. Medizinische Klinik und Poliklinik, University Medical Center, Hamburg, GermanyRenal Division, Peking University First Hospital, Beijing, ChinaTo date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases.http://www.sciencedirect.com/science/article/pii/S2468024916300481autoimmunityinflammationlupusrejectionstem cellsvasculitis |